SCYNEXIS INC (SCYX)
$5.40-$0.13 (-2.36%) Today
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 10 | 28,750 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
17 Form 4 filings on record, the earliest from Apr 9, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Brian Philippe Tinmouth | Grant or award | Common Stock | 2,875 | $0.00 | - | |
| Brian Philippe Tinmouth | Grant or award | Stock Option (Right to Buy) | 2,875 | $0.00 | - | |
| Guy Macdonald | Grant or award | Common Stock | 2,875 | $0.00 | - | |
| Guy Macdonald | Grant or award | Stock Option (Right to Buy) | 2,875 | $0.00 | - | |
| Armando Anido | Grant or award | Stock Option (Right to Buy) | 2,875 | $0.00 | - | |
| Armando Anido | Grant or award | Common Stock | 2,875 | $0.00 | - | |
| David C. Hastings | Grant or award | Common Stock | 2,875 | $0.00 | - | |
| David C. Hastings | Grant or award | Stock Option (Right to Buy) | 2,875 | $0.00 | - | |
| Ann Hanham | Grant or award | Stock Option (Right to Buy) | 2,875 | $0.00 | - | |
| Ann Hanham | Grant or award | Common Stock | 2,875 | $0.00 | - | |
| Gonzalez David Angulo - Officer | Open-market purchase | Common Stock | 108,695 | - | - | |
| Gonzalez David Angulo - Officer | Open-market purchase | Warrant to Purchase Common Stock | 108,695 | - | - | |
| Ivor Macleod - Officer | Grant or award | Common Stock | 129,833 | $0.00 | - | |
| Scott Sukenick - Officer | Grant or award | Common Stock | 129,833 | $0.00 | - | |
| Gonzalez David Angulo - Officer | Grant or award | Common Stock | 391,333 | $0.00 | - | |
| Gonzalez David Angulo - Officer | Grant or award | Common Stock | 32,500 | $6.08 | $25K | |
| Brian Philippe Tinmouth | Grant or award | Common Stock | 23,000 | $0.00 | - | |
| Brian Philippe Tinmouth | Grant or award | Stock Option | 23,000 | $0.00 | - | |
| David C. Hastings | Grant or award | Common Stock | 23,000 | $0.00 | - | |
| David C. Hastings | Grant or award | Stock Option | 23,000 | $0.00 | - | |
| Armando Anido | Grant or award | Common Stock | 23,000 | $0.00 | - | |
| Armando Anido | Grant or award | Stock Option | 23,000 | $0.00 | - | |
| Steven C. Gilman | Grant or award | Common stock | 23,000 | $0.00 | - | |
| Steven C. Gilman | Grant or award | Stock Option | 23,000 | $0.00 | - | |
| Ann Hanham | Grant or award | Common Stock | 23,000 | $0.00 | - | |
| Ann Hanham | Grant or award | Stock Option | 23,000 | $0.00 | - | |
| Guy Macdonald | Grant or award | Common Stock | 23,000 | $0.00 | - | |
| Guy Macdonald | Grant or award | Stock Option | 23,000 | $0.00 | - | |
| Gonzalez David Angulo - Officer | Grant or award | Common Stock | 23,000 | $6.72 | $19K |
SCYNEXIS INC (SCYX) had 5 insider filings in the last 90 days, with the most recent on 2026-06-30. The full record for SCYX runs to 17 Form 4 filings, the earliest from 2025-04-09. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of SCYX were filed in the last 90 days. 2 purchases are on record for this company.
No insider sales of SCYX were filed in the last 90 days.
This page tracks SCYX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add SCYX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
